What is it about?
AT-527 forms an active metabolite, AT-9010, in the liver, that specifically inhibits an HCV enzyme, which is highly conserved and essential for the virus to replicate. AT-527 is 10 times more potent than the currently accepted treatment, sofosbuvir, especially against resistant variants of the virus, but it is not toxic nor does it affect other liver enzymes.
Featured Image
Photo by Fusion Medical Animation on Unsplash
Why is it important?
When used as part of an HCV treatment regimen, our findings suggest that AT-527 may improve the cure rate, especially for patients with difficult to treat genotypes and resistant variants of the virus, and it may shorten the duration of the treatment.
Perspectives
Due to its clinically proven efficacy and safety, AT-527 has the potential to shift the treatment paradigm for HCV, regardless of virus genotype and patient cirrhotic status.
Steven Good
Atea Pharmaceuticals, Inc.
Read the Original
This page is a summary of: Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus, PLoS ONE, January 2020, PLOS, DOI: 10.1371/journal.pone.0227104.
You can read the full text:
Contributors
The following have contributed to this page
